Raffaele Antonelli Incalzi
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Volatile Organic Compounds | 6 | 2021 | 187 | 2.35 | Why? |
| Electronic Nose | 4 | 2018 | 36 | 2.21 | Why? |
| Breath Tests | 6 | 2018 | 338 | 2.13 | Why? |
| Electrochemical Techniques | 2 | 2019 | 406 | 1.09 | Why? |
| Pulmonary Disease, Chronic Obstructive | 5 | 2021 | 3832 | 0.87 | Why? |
| Glomerular Filtration Rate | 3 | 2018 | 1262 | 0.80 | Why? |
| Drug Resistance, Multiple, Bacterial | 2 | 2018 | 1115 | 0.78 | Why? |
| Adrenergic Fibers | 1 | 2018 | 3 | 0.77 | Why? |
| Leg Ulcer | 1 | 2019 | 32 | 0.74 | Why? |
| Porins | 1 | 2018 | 45 | 0.73 | Why? |
| Asbestos | 1 | 2017 | 45 | 0.68 | Why? |
| Lung Diseases, Obstructive | 1 | 2017 | 46 | 0.68 | Why? |
| Sympathetic Nervous System | 1 | 2018 | 111 | 0.67 | Why? |
| Pleural Diseases | 1 | 2017 | 68 | 0.64 | Why? |
| Frailty | 4 | 2021 | 1432 | 0.64 | Why? |
| Primary Dysautonomias | 1 | 2017 | 107 | 0.63 | Why? |
| Vital Capacity | 1 | 2017 | 399 | 0.60 | Why? |
| Mean Platelet Volume | 1 | 2017 | 203 | 0.60 | Why? |
| Molecular Epidemiology | 2 | 2018 | 1638 | 0.59 | Why? |
| Diaphragm | 1 | 2018 | 232 | 0.58 | Why? |
| Forced Expiratory Volume | 1 | 2017 | 632 | 0.55 | Why? |
| Exhalation | 1 | 2018 | 441 | 0.55 | Why? |
| Ultrasonography | 4 | 2019 | 4409 | 0.51 | Why? |
| Pseudomonas aeruginosa | 1 | 2018 | 652 | 0.51 | Why? |
| Methotrexate | 1 | 2017 | 471 | 0.51 | Why? |
| Learning | 1 | 2021 | 1181 | 0.49 | Why? |
| Cognition | 2 | 2021 | 1394 | 0.48 | Why? |
| Rome | 3 | 2018 | 497 | 0.47 | Why? |
| Klebsiella Infections | 1 | 2017 | 466 | 0.47 | Why? |
| Urinary Tract Infections | 1 | 2018 | 534 | 0.46 | Why? |
| Smell | 1 | 2021 | 1851 | 0.45 | Why? |
| Sleep Apnea, Obstructive | 2 | 2017 | 668 | 0.45 | Why? |
| Klebsiella pneumoniae | 1 | 2017 | 658 | 0.44 | Why? |
| Cytochrome P-450 CYP3A | 1 | 2019 | 88 | 0.38 | Why? |
| Renal Insufficiency, Chronic | 2 | 2018 | 2654 | 0.38 | Why? |
| Phylogeny | 2 | 2018 | 13341 | 0.37 | Why? |
| Loneliness | 1 | 2021 | 1766 | 0.37 | Why? |
| Cardiac Output, Low | 1 | 2018 | 31 | 0.36 | Why? |
| Heart | 1 | 2018 | 1791 | 0.36 | Why? |
| Accidental Falls | 2 | 2019 | 448 | 0.35 | Why? |
| Disabled Persons | 2 | 2018 | 1152 | 0.34 | Why? |
| Pyridazines | 1 | 2018 | 86 | 0.34 | Why? |
| Aorta, Thoracic | 1 | 2009 | 271 | 0.33 | Why? |
| Public Health Surveillance | 2 | 2018 | 3129 | 0.33 | Why? |
| Hydrazones | 1 | 2018 | 216 | 0.32 | Why? |
| Homocysteine | 1 | 2017 | 83 | 0.32 | Why? |
| Whole Genome Sequencing | 1 | 2017 | 3239 | 0.31 | Why? |
| Myocardium | 1 | 2018 | 2323 | 0.31 | Why? |
| Early Detection of Cancer | 1 | 2018 | 1956 | 0.30 | Why? |
| Sleep | 1 | 2018 | 2695 | 0.30 | Why? |
| Aged | 40 | 2021 | 215776 | 0.30 | Why? |
| Italy | 22 | 2021 | 38444 | 0.29 | Why? |
| Cross Infection | 2 | 2018 | 8675 | 0.29 | Why? |
| Folic Acid | 1 | 2017 | 172 | 0.29 | Why? |
| Cardiotonic Agents | 1 | 2018 | 418 | 0.28 | Why? |
| Heart Failure | 3 | 2018 | 6638 | 0.28 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 1261 | 0.28 | Why? |
| Geriatric Assessment | 4 | 2021 | 1372 | 0.27 | Why? |
| Accelerometry | 1 | 2015 | 228 | 0.26 | Why? |
| Mass Screening | 3 | 2021 | 8005 | 0.26 | Why? |
| Arthritis, Rheumatoid | 1 | 2017 | 2043 | 0.26 | Why? |
| Reproducibility of Results | 5 | 2021 | 11304 | 0.25 | Why? |
| Health Services for the Aged | 1 | 2020 | 602 | 0.25 | Why? |
| Antirheumatic Agents | 1 | 2017 | 3023 | 0.24 | Why? |
| Health Status | 3 | 2021 | 3259 | 0.23 | Why? |
| Drug Interactions | 1 | 2019 | 1653 | 0.23 | Why? |
| Frail Elderly | 3 | 2021 | 1427 | 0.22 | Why? |
| Decision Support Systems, Clinical | 1 | 2017 | 551 | 0.22 | Why? |
| Monitoring, Ambulatory | 1 | 2015 | 343 | 0.22 | Why? |
| Independent Living | 2 | 2018 | 842 | 0.22 | Why? |
| Urinary Bladder Neoplasms | 1 | 2017 | 614 | 0.21 | Why? |
| Lung Neoplasms | 1 | 2018 | 3228 | 0.21 | Why? |
| Activities of Daily Living | 4 | 2021 | 1530 | 0.21 | Why? |
| Sweat | 1 | 2021 | 127 | 0.21 | Why? |
| Mental Status and Dementia Tests | 1 | 2021 | 208 | 0.21 | Why? |
| Respiratory Tract Diseases | 1 | 2018 | 1061 | 0.21 | Why? |
| Male | 38 | 2021 | 367725 | 0.21 | Why? |
| Lung | 3 | 2018 | 31049 | 0.21 | Why? |
| Continuity of Patient Care | 1 | 2020 | 1574 | 0.20 | Why? |
| Female | 38 | 2021 | 380317 | 0.20 | Why? |
| Humans | 57 | 2021 | 930598 | 0.20 | Why? |
| Varicose Ulcer | 1 | 2019 | 8 | 0.20 | Why? |
| Patient Acceptance of Health Care | 1 | 2018 | 5002 | 0.20 | Why? |
| Geriatrics | 1 | 2019 | 947 | 0.19 | Why? |
| Spinal Curvatures | 1 | 2019 | 28 | 0.19 | Why? |
| Predictive Value of Tests | 4 | 2018 | 9537 | 0.19 | Why? |
| Collagen Type IV | 1 | 2018 | 12 | 0.19 | Why? |
| Tyrosine 3-Monooxygenase | 1 | 2018 | 32 | 0.19 | Why? |
| Occupational Exposure | 1 | 2017 | 4742 | 0.18 | Why? |
| Maximal Midexpiratory Flow Rate | 1 | 2017 | 15 | 0.18 | Why? |
| Anti-Ulcer Agents | 1 | 2017 | 24 | 0.18 | Why? |
| S-Adenosylmethionine | 1 | 2018 | 137 | 0.18 | Why? |
| Discriminant Analysis | 1 | 2018 | 170 | 0.18 | Why? |
| Postural Balance | 1 | 2019 | 144 | 0.18 | Why? |
| Aging | 2 | 2019 | 3581 | 0.18 | Why? |
| Antiparkinson Agents | 1 | 2019 | 125 | 0.18 | Why? |
| Peak Expiratory Flow Rate | 1 | 2017 | 64 | 0.17 | Why? |
| Carcinogens | 1 | 2017 | 33 | 0.17 | Why? |
| Aged, 80 and over | 20 | 2021 | 88759 | 0.17 | Why? |
| Posterior Leukoencephalopathy Syndrome | 1 | 2021 | 213 | 0.17 | Why? |
| Least-Squares Analysis | 1 | 2018 | 254 | 0.17 | Why? |
| Cluster Analysis | 3 | 2018 | 3001 | 0.17 | Why? |
| Risk Assessment | 3 | 2017 | 25439 | 0.17 | Why? |
| Algorithms | 3 | 2017 | 7346 | 0.16 | Why? |
| Melanoma | 1 | 2017 | 1229 | 0.16 | Why? |
| Molecular Typing | 1 | 2017 | 280 | 0.15 | Why? |
| Monitoring, Physiologic | 1 | 2017 | 1956 | 0.15 | Why? |
| Reference Values | 1 | 2018 | 795 | 0.15 | Why? |
| Fluorescent Antibody Technique | 1 | 2018 | 835 | 0.15 | Why? |
| Walk Test | 1 | 2018 | 461 | 0.15 | Why? |
| Disability Evaluation | 1 | 2019 | 671 | 0.14 | Why? |
| Carbapenems | 1 | 2018 | 343 | 0.14 | Why? |
| Wound Healing | 1 | 2019 | 424 | 0.14 | Why? |
| Mental Health | 1 | 2021 | 15770 | 0.14 | Why? |
| Inflammation | 3 | 2020 | 13255 | 0.14 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.13 | Why? |
| Smartphone | 1 | 2015 | 1840 | 0.13 | Why? |
| Dogs | 1 | 2021 | 2529 | 0.13 | Why? |
| Pseudomonas Infections | 1 | 2018 | 425 | 0.13 | Why? |
| Psychiatric Status Rating Scales | 2 | 2017 | 1340 | 0.13 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2018 | 451 | 0.13 | Why? |
| Psychometrics | 1 | 2021 | 1269 | 0.13 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2018 | 4545 | 0.13 | Why? |
| Hair | 1 | 2005 | 175 | 0.12 | Why? |
| Middle Aged | 19 | 2021 | 270681 | 0.12 | Why? |
| Sarcopenia | 1 | 2018 | 422 | 0.12 | Why? |
| Physical Examination | 1 | 2019 | 755 | 0.12 | Why? |
| Giant Cell Arteritis | 1 | 2005 | 137 | 0.12 | Why? |
| Exercise Tolerance | 1 | 2018 | 634 | 0.12 | Why? |
| Health Surveys | 2 | 2021 | 2841 | 0.12 | Why? |
| Healthy Volunteers | 1 | 2018 | 1444 | 0.12 | Why? |
| Proton Pump Inhibitors | 1 | 2017 | 377 | 0.12 | Why? |
| Polysomnography | 1 | 2013 | 296 | 0.12 | Why? |
| Internal Medicine | 1 | 2018 | 557 | 0.12 | Why? |
| Sequence Alignment | 1 | 2018 | 2109 | 0.11 | Why? |
| Alanine Transaminase | 1 | 2018 | 1329 | 0.11 | Why? |
| Self Report | 2 | 2021 | 3802 | 0.11 | Why? |
| Hospitalization | 6 | 2020 | 54280 | 0.11 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2018 | 5837 | 0.11 | Why? |
| Biomarkers | 5 | 2019 | 23361 | 0.10 | Why? |
| Olfaction Disorders | 1 | 2019 | 3704 | 0.10 | Why? |
| Base Sequence | 1 | 2018 | 3581 | 0.10 | Why? |
| Natriuretic Peptide, Brain | 1 | 2017 | 1215 | 0.10 | Why? |
| Kaplan-Meier Estimate | 2 | 2017 | 4260 | 0.10 | Why? |
| Early Diagnosis | 1 | 2019 | 2443 | 0.10 | Why? |
| Proportional Hazards Models | 3 | 2018 | 6543 | 0.10 | Why? |
| Depressive Disorder | 2 | 2017 | 1236 | 0.10 | Why? |
| Smoking | 2 | 2021 | 3358 | 0.10 | Why? |
| Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.10 | Why? |
| Prospective Studies | 5 | 2019 | 43301 | 0.09 | Why? |
| Postoperative Complications | 1 | 2018 | 5861 | 0.09 | Why? |
| Disease Outbreaks | 1 | 2017 | 27595 | 0.09 | Why? |
| Atherosclerosis | 1 | 2017 | 768 | 0.09 | Why? |
| Hygiene | 1 | 2005 | 987 | 0.09 | Why? |
| Bayes Theorem | 1 | 2017 | 3237 | 0.08 | Why? |
| Thrombosis | 1 | 2009 | 7504 | 0.08 | Why? |
| Creatinine | 2 | 2018 | 1443 | 0.08 | Why? |
| Antioxidants | 1 | 2017 | 1593 | 0.08 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.08 | Why? |
| Atrial Fibrillation | 1 | 2021 | 2320 | 0.08 | Why? |
| Parkinson Disease | 1 | 2019 | 1414 | 0.08 | Why? |
| Peptide Fragments | 1 | 2017 | 2075 | 0.08 | Why? |
| Acceleration | 1 | 2015 | 26 | 0.08 | Why? |
| Polypharmacy | 1 | 2019 | 347 | 0.08 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.08 | Why? |
| Hypertension | 2 | 2020 | 8895 | 0.07 | Why? |
| Risk Factors | 9 | 2021 | 71621 | 0.07 | Why? |
| Surveys and Questionnaires | 5 | 2021 | 43792 | 0.07 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.07 | Why? |
| Hospitals | 2 | 2018 | 11793 | 0.07 | Why? |
| Body Mass Index | 1 | 2018 | 4306 | 0.07 | Why? |
| Alzheimer Disease | 1 | 2005 | 1020 | 0.07 | Why? |
| Hospitals, University | 1 | 2017 | 4173 | 0.07 | Why? |
| Liver Cirrhosis | 1 | 2016 | 1810 | 0.07 | Why? |
| Obesity | 1 | 2005 | 7388 | 0.07 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.07 | Why? |
| Diet | 1 | 2017 | 2052 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.07 | Why? |
| Adult | 11 | 2021 | 244371 | 0.07 | Why? |
| Models, Molecular | 1 | 2018 | 7616 | 0.07 | Why? |
| Time Factors | 2 | 2017 | 31397 | 0.07 | Why? |
| Prevalence | 5 | 2021 | 25773 | 0.07 | Why? |
| Odds Ratio | 3 | 2021 | 5861 | 0.06 | Why? |
| Population Surveillance | 1 | 2020 | 4967 | 0.06 | Why? |
| Sensitivity and Specificity | 3 | 2019 | 22971 | 0.06 | Why? |
| Prognosis | 4 | 2018 | 32490 | 0.06 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 2426 | 0.06 | Why? |
| Respiration | 1 | 2018 | 729 | 0.06 | Why? |
| Hospital Bed Capacity | 1 | 2020 | 1300 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.06 | Why? |
| Fever | 2 | 2021 | 7795 | 0.06 | Why? |
| Antineoplastic Agents | 1 | 2018 | 3550 | 0.06 | Why? |
| Nursing Homes | 1 | 2019 | 4155 | 0.06 | Why? |
| ROC Curve | 3 | 2020 | 6024 | 0.06 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.05 | Why? |
| Liver Diseases | 1 | 2016 | 2698 | 0.05 | Why? |
| Organizational Innovation | 1 | 2020 | 2468 | 0.05 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.05 | Why? |
| Immunohistochemistry | 1 | 2017 | 2275 | 0.05 | Why? |
| Neprilysin | 1 | 2020 | 112 | 0.05 | Why? |
| Logistic Models | 3 | 2021 | 9089 | 0.05 | Why? |
| Patient Care | 1 | 2010 | 1664 | 0.05 | Why? |
| Models, Theoretical | 1 | 2018 | 6659 | 0.05 | Why? |
| Multivariate Analysis | 2 | 2021 | 5440 | 0.05 | Why? |
| Mortality | 2 | 2020 | 7132 | 0.05 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.04 | Why? |
| Protons | 1 | 2017 | 64 | 0.04 | Why? |
| Total Lung Capacity | 1 | 2017 | 40 | 0.04 | Why? |
| Nonlinear Dynamics | 1 | 2018 | 177 | 0.04 | Why? |
| Norway | 1 | 2021 | 1004 | 0.04 | Why? |
| Regression Analysis | 2 | 2017 | 2484 | 0.04 | Why? |
| Longevity | 1 | 2018 | 159 | 0.04 | Why? |
| Brachial Artery | 1 | 2017 | 107 | 0.04 | Why? |
| Depression | 2 | 2018 | 14116 | 0.04 | Why? |
| Vitamin E | 1 | 2017 | 128 | 0.04 | Why? |
| Waist Circumference | 1 | 2017 | 199 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Dyspnea | 1 | 2019 | 3847 | 0.04 | Why? |
| Carotid Intima-Media Thickness | 1 | 2017 | 179 | 0.04 | Why? |
| Transplantation, Autologous | 1 | 2017 | 364 | 0.04 | Why? |
| Point-of-Care Systems | 1 | 2019 | 2955 | 0.04 | Why? |
| Health Services Needs and Demand | 1 | 2020 | 3419 | 0.04 | Why? |
| Telemedicine | 1 | 2017 | 25032 | 0.04 | Why? |
| Cardiovascular Diseases | 2 | 2018 | 11497 | 0.04 | Why? |
| Patient Discharge | 1 | 2010 | 5696 | 0.03 | Why? |
| Energy Intake | 1 | 2017 | 323 | 0.03 | Why? |
| Animals | 2 | 2021 | 78931 | 0.03 | Why? |
| Kidney Failure, Chronic | 1 | 2010 | 3222 | 0.03 | Why? |
| Databases, Factual | 1 | 2019 | 6248 | 0.03 | Why? |
| Syndrome | 1 | 2019 | 1310 | 0.03 | Why? |
| Spirometry | 1 | 2017 | 524 | 0.03 | Why? |
| Administration, Oral | 1 | 2021 | 2340 | 0.03 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2019 | 9893 | 0.03 | Why? |
| Area Under Curve | 1 | 2020 | 2564 | 0.03 | Why? |
| Internet | 2 | 2021 | 6204 | 0.03 | Why? |
| Intracranial Hemorrhages | 1 | 2021 | 1170 | 0.03 | Why? |
| Seizures | 1 | 2021 | 1163 | 0.03 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.03 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.03 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.03 | Why? |
| Cross-Sectional Studies | 4 | 2021 | 53120 | 0.03 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.03 | Why? |
| Interleukin-6 | 1 | 2019 | 7522 | 0.03 | Why? |
| Prednisone | 1 | 2005 | 652 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2018 | 48226 | 0.02 | Why? |
| Neoplasms | 1 | 2018 | 17251 | 0.02 | Why? |
| Kidney Function Tests | 1 | 2010 | 520 | 0.02 | Why? |
| Phenotype | 1 | 2019 | 4037 | 0.02 | Why? |
| Comorbidity | 2 | 2018 | 34796 | 0.02 | Why? |
| Cognitive Dysfunction | 1 | 2018 | 1389 | 0.02 | Why? |
| Dementia | 1 | 2019 | 1861 | 0.02 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.02 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Echocardiography | 1 | 2017 | 3661 | 0.02 | Why? |
| Spain | 1 | 2021 | 15545 | 0.01 | Why? |
| Blood Pressure | 1 | 2003 | 2198 | 0.01 | Why? |
| Alcohol Drinking | 1 | 2003 | 1663 | 0.01 | Why? |
| Registries | 1 | 2021 | 12327 | 0.01 | Why? |
| Seasons | 1 | 2003 | 4071 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2019 | 17020 | 0.01 | Why? |
| C-Reactive Protein | 1 | 2017 | 7972 | 0.01 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.01 | Why? |
| Anticoagulants | 1 | 2021 | 9563 | 0.01 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.01 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.01 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Disease Progression | 1 | 2005 | 13580 | 0.01 | Why? |
| Anti-Inflammatory Agents | 1 | 2005 | 6153 | 0.01 | Why? |
| Treatment Outcome | 1 | 2021 | 51732 | 0.01 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.01 | Why? |